Showing 6351-6360 of 7313 results for "".
- Lisa M. Donofrio, MD Takes Reins of ASDS/ASDSAhttps://practicaldermatology.com/news/lisa-m-donofrio-md-takes-reins-of-asdsasdsa/2458023/Lisa M. Donofrio, MD, is the new President of the American Society for Dermatologic Surgery (ASDS) and American Society for Dermatologic Surgery Association (ASDSA). Along with her fellow officers and the ASDS / ASDSA
- Medicaid Patients May Receive Less Timely Melanoma Surgeryhttps://practicaldermatology.com/news/medicaid-patients-may-receive-less-timely-melanoma-surgery/2458028/Delays in melanoma surgery may vary by insurance type, according to research in JAMA Dermatology. While Medicaid patients had the highest likelihood of delays, significant pro
- SmartGraft Taps Industry Vet as New EVPhttps://practicaldermatology.com/news/smartgraft-taps-new-evp/2458031/Joseph R. Brown is the new Executive Vice President for SmartGraft®, a minimally invasive hair restoration
- Sculpsure Cleared to Treat Double Chinshttps://practicaldermatology.com/news/sculpsure-cleared-to-treat-double-chins/2458036/Cynosure's SculpSure® is now cleared for submental fat reduction. The U.S. Food and Drug Administration (FDA) granted an expanded FDA 510(k) clearance for this area, Hologic, Inc. reports.
- Castle Creek Pharmaceuticals Unveils First-Ever IGA Scale for EBS Clinical Researchhttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-unveils-first-ever-iga-scale-for-ebs-clinical-research/2458035/Castle Creek Pharmaceuticals (CCP) has developed and validated the first Investigator's Global Assessment (IGA) scale to be used by clinicians evaluating the average overall severity of epidermolysis bullosa simplex (EBS) lesions in clinical tria
- Sciton and the Young Survival Coalition Partner for Breast Cancer Awarenesshttps://practicaldermatology.com/news/sciton-and-the-young-survival-coalition-partner-for-breast-cancer-awareness/2458041/Sciton, Inc.’s Women's Health Group division and the Young Survival Coalition (YSC) are partnering to raise awareness about women's vaginal health, in particular, those who are recovering from breast can
- New Data: Aclaris' A-101 40% Safely Banishes Facial SK Lesionshttps://practicaldermatology.com/news/new-data-aclaris-a-101-40-safely-banishes-facial-sk-lesions/2458044/Good news for Aclaris. New data suggest that their drug candidate A-101 40 percent may be an appealing option to remove seborrheic keratosis (SK) lesions in highly visible areas, such as the face, with minimal risk of s
- New Label Reflects Sustained Response for Sun Pharma's Odomzo in BCChttps://practicaldermatology.com/news/new-label-reflects-sustained-response-for-sun-pharmas-odomzo-in-bcc/2458045/Sun Pharma’s new Odomzo® (Sonidegib) label incorporates long-term data showing sustained duration of response of 26 months in treatment of locally advanced basal cell carcinoma. Odomzo® is an oral hedgehog inhibitor indicated for t
- FDA Accepts NDAs for Review of Binimetinib And Encorafenib for Advanced BRAF-mutant Melanomahttps://practicaldermatology.com/news/fda-accepts-ndas-for-review-of-binimetinib-and-encorafenib-for-advanced-braf-mutant-melanoma/2458058/The FDA has accepted Array BioPharma's New Drug Applications (NDAs) to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The FDA se
- DermTech Appoints Dr. Gerald Krueger to Scientific Advisory Boardhttps://practicaldermatology.com/news/dermtech-appoints-dr-gerald-krueger-to-scientific-advisory-board/2458059/DermTech, Inc. has appointed Gerald G. Krueger, MD, to its Scientific Advisory Board. Dr. Krueger is Professor of Dermatology and Edna Benning Presidential Endowed Chair at the University of Utah in Salt Lake City, UT. He received his m